Active substance
Praziquantel
- SFDA 1
- US FDA 2
- US price lines 1
- WHO EML 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BILTRICIDE 600MG TABS | 600 mg | Film-coated tablet · Oral use | 4 Blister | SAR 65.90 | NCE · Prescription | BAYER AG | Valid |
Indications — CHI Daman Drug Formulary
RENAL TRANSPLANT; SCHISTOSOMIASIS; TAENIASIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PRAZIQUANTEL | 600MG | tablet · oral | PH HEALTH | Prescription | 27 Nov 2017 |
| BILTRICIDE | 600MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | BAYER HLTHCARE | Discontinued | 29 Dec 1982 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PRAZIQUANTEL 600 MG TABLET | $53.24776 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.1.4. Cysticidal medicines · complementary
Cysticercosis of central nervous system
Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg - 6.1.3. Antischistosomals and other antitrematode medicines · core
Paragonimiasis; Clonorchiasis; Opisthorchiasis; Schistosomiasis
Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg - 6.1.1. Intestinal anthelminthics · core
Diphyllobothriasis; Taeniasis due to Taenia saginata; Hymenolepiasis; Taeniasis due to Taenia solium
Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
Safety signals and safety-related labeling changes
- US FDA 19 Dec 2023 BILTRICIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.